Home » Posts tagged with » gene therapy
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy. Currently, nadofaragene firadenovec is in late-stage development for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). […]

Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma

Cellectis said that it has dosed the first patient in a phase 1  study – the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf CAR-T product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM). The French gene therapy company began the phase 1 dose-escalation study after getting clearance from the US Food […]

Continue reading …
Apic Bio bags FDA orphan designation for ALS SOD1 gene therapy APB-102

US gene therapy company Apic Bio said that APB-102, its ALS SOD1 gene therapy, has been granted orphan drug designation by the US Food and Drug Administration (FDA). APB-102 is expected to shortly enter into clinical development for the genetic disorder – SOD1 amyotrophic lateral sclerosis (ALS). The orphan designation is given to novel drugs […]

Continue reading …
US CDMO Brammer Bio to be acquired by Thermo Fisher

Thermo Fisher acquisition of Brammer Bio : Thermo Fisher Scientific, a global life sciences company, has agreed to buy US-based viral vector contract development and manufacturing organization (CDMO) Brammer Bio for $1.7 billion in an all-cash transaction. Thermo Fisher acquisition of Brammer Bio Brammer Bio, which is owned by Ampersand Capital Partners, is focused on […]

Continue reading …
SIRION Biotech opens new office in Massachusetts

CAMBRIDGE, Mass.–(BUSINESS WIRE)–SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (“SIRION”), offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies, today announced the grand opening of a new office at 125 Cambridgepark Drive, Suite 301, Cambridge, Massachusetts 02140. SIRION was pleased to meet its new neighbors last night […]

Continue reading …
US FDA approves Spark’s gene therapy Luxturna for rare form of vision loss

Luxturna FDA approval : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics has secured the approval from the US Food and Drug Administration (FDA) for a rare inherited type of vision loss affecting children and adults that could result in blindness if left untreated. Luxturna is an adeno-associated viral (AAV) vector gene therapy which […]

Continue reading …
Panel recommends Luxturna FDA approval for rare form of blindness

Luxturna FDA approval news : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics is closing in towards an FDA approval for treating blindness due to an inherited retinal disease (IRD), following the recommendation from an advisory panel of the US drug regulator. An adeno-associated viral (AAV) vector gene therapy, Luxturna has been recommended to […]

Continue reading …